Ertugliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor in Phase III clinical trials for the treatment of type 2 diabetes. The drug was originally developed by Pfizer, until the company entered into a licensing agreement with Merck & Co in 2013, under which Merck receives 60% of revenue and costs in the US and EU, and Pfizer receives milestone payments. Pfizer’s partnership with Merck also allows for fixed-dose combinations with Januvia (sitagliptin; Merck & Co).
Ertugliflozin exerts its pharmacological effect by inhibiting SGLT-2, which is expressed almost exclusively in the kidney. Located in the proximal tubule, the SGLT-2 transport system is involved in the reabsorption of glucose. As such, inhibition of the transport protein prevents glucose reabsorption, resulting in excretion through the urine.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 ertugliflozin : Diabetes type 2
LIST OF TABLES 9 Figure 1: Ertugliflozin for type 2 diabetes – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of ertugliflozin for type 2 diabetes
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of ertugliflozin for type 2 diabetes
13 Figure 4: Ertugliflozin franchise sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF FIGURES 5 Table 1: Ertugliflozin drug profile
6 Table 2: Ertugliflozin Phase III data in type 2 diabetes
9 Table 3: Ertugliflozin Phase III trials in type 2 diabetes
14 Table 4: Ertugliflozin franchise sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m),
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.